Insights from acute myeloid leukemia suggest that receptor tyrosine kinase mutations, secondary IDH mutations, and isoform switching (e.g., IDH1 to IDH2) can mediate resistance [161]. The gene discussed is IDH2; the disease is acute myeloid leukemia.